Mark Cuban Cost Plus Drug Company (MCCPDC) has forged a strategic partnership with Lupin Limited, a multinational pharmaceutical firm, and the COPD Foundation, with the aim of broadening access to Tiotropium Bromide Inhalation Powder for individuals suffering from chronic obstructive pulmonary disease (COPD) in the United States.
COPD is a persistent inflammatory lung ailment characterised by airflow obstruction, resulting in breathing difficulties. Tiotropium Bromide serves as a remedy for lung conditions by inducing relaxation in the muscles surrounding the airways, facilitating improved breathing.
Tiotropium Bromide Inhalation Powder, accessible through the pharmaceutical company headquartered in Mumbai, constitutes the generic equivalent of Spiriva HandiHaler, originally developed by Germany's Boehringer Ingelheim Pharmaceuticals.
Alex Oshmyansky, the CEO of Mark Cuban Cost Plus Drug Company, expressed enthusiasm for the collaboration, stating, "We are thrilled to collaborate with Lupin and the COPD Foundation in the mission to offer more affordable prescription medications to consumers. Cost Plus Drugs, Lupin, and the COPD Foundation all share a common objective: ensuring that consumers have access to the most competitively priced prescription medications. With Cost Plus Drugs, consumers can have confidence in receiving equitable pricing and the convenience of having their medication delivered directly to their doorstep."
COPD impacts approximately 15 million adults in the United States, making it the fourth leading cause of mortality in the country, as reported by the National Institutes of Health's Heart, Lung, and Blood Institute (NIH HLBI).
Numerous digital health enterprises are dedicated to assisting COPD patients, including Wellinks, headquartered in Connecticut, which provides a digital platform and interconnected devices tailored for COPD management, and Kaia Health, based in New York, which delivers clinical capabilities and treatment services for individuals seeking care for chronic obstructive pulmonary disease in both the United States and Europe.
Click here to read the original news story.